Accessibility Menu
Theralink Technologies logo

Theralink Technologies(OTC) OBMP

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-100%
5 Year-100%
1 Year+0%
1 Month+0%
N/A
Theralink Technologies last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-28
Theralink Technologies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-07
1 month+0%USD 0.002026-07-16
3 month+0%USD 0.002026-05-28
Year to date+0%USD 0.002025-12-31
1 year+0%USD 0.002025-08-14
3 year-99.92%USD 0.002023-08-29
5 year-100%USD 0.352021-08-27
Since inception-100%USD 337.512015-09-11

Theralink Technologies Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$284.67K

Net Income (TTM)

-$5.96M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

OBMP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Theralink Technologies

Theralink Technologies, Inc. is a precision medicine and molecular data company focused on developing and commercializing innovative cancer immunotherapies. Utilizing a patented biomarker platform, the company provides critical insights for oncology treatment, aiding both biopharmaceutical firms and clinical oncologists.

Products and Services
  • Theralink Reverse Phase Protein Array assays for oncology insights
  • Advanced laboratory-developed test technology for drug response prediction
  • Precision medicine solutions targeting various oncology areas
Growth Outlook
  • Recent quarterly revenue increased to $78,975, reflecting growing market interest
  • Strong gross profit margin of 44.8% in Q4 2021 indicates operational efficiency
  • Continued investment in R&D expected to drive future product development
Financial Highlights
  • Trailing twelve months (TTM) revenue of $305,000 shows significant growth potential
  • Operating expenses decreased from $1,462,000 in Q4 2021 to $1,416,000 in Q3 2021
  • Cash and cash equivalents increased to $414,982, providing liquidity for operations
Theralink Technologies, Inc. operates in the biotechnology sector, specifically focusing on oncology. The company has made strides in developing its proprietary assays, which are essential for understanding patient responses to various treatments. The recent financial data indicates a positive trend in revenue and operational efficiency, suggesting that the company is on a path toward sustainable growth. The increase in cash reserves also positions Theralink favorably for future investments and operational needs. As the demand for precision medicine continues to rise, Theralink's innovative solutions may play a crucial role in shaping the future of cancer treatment.
AI Generated • Aug 21, 2026

Industry

Biotechnology

Sector

Health Care

Employees

16

CEO

Faith Zaslavsky

Website

www.theralink.com

Headquarters

Golden, CO 80401, US

OBMP Financials

Key Financial Metrics (TTM)

Gross Margin

79.20%

Operating Margin

-1479.80%

Net Income Margin

-5093.56%

Return on Equity

147.47%

Return on Capital

N/A

Return on Assets

-1084.55%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

-0.09%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$192.18K

Operating Income

-$5.50M

EBITDA

-$5.32M

Operating Cash Flow

-$4.84M

Capital Expenditure

-$144.34K

Free Cash Flow

-$4.99M

Cash & ST Invst.

$431.38K

Total Debt

$1.60M

Theralink Technologies Performance Analysis

Theralink Technologies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-09-30USD 505,604N/A
20222022-09-30USD 567,90512.3%
20232023-09-30USD 606,7966.8%
Theralink Technologies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32020-09-30N/A
Q42020-12-31-90.7%
Q32021-09-30N/A
Q42021-12-31-12.8%
Theralink Technologies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-09-30USD -0.00N/A
20222022-09-30USD -0.0083.3%
20232023-09-30USD -0.01127.3%
Theralink Technologies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32020-09-30N/A
Q42020-12-3190.3%
Q32021-09-30N/A
Q42021-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2021YOY CHG

Revenue

$78.98K

N/A

Gross Profit

$35.41K

N/A

Gross Margin

44.84%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

16

N/A

Net Income

-$1.65M

+39.4%

EBITDA

-$1.33M

+33.2%

Quarterly Fundamentals

Name
Q4 2021YOY CHG

Total Cash

$431.38K

+1907.5%

Total Debt

$1.60M

-54.1%

Accounts Receivable

$75.32K

N/A

Inventory

$21.71K

N/A

Long Term Debt

$1.42M

N/A

Short Term Debt

$172.89K

-95.0%

Return on Assets

-10.85%

N/A

Return on Invested Capital

24.28%

N/A

Free Cash Flow

-$1.49M

-339.8%

Operating Cash Flow

-$1.49M

-339.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IPSEFIpsen S.A.
$113.13+0.00%
UHSUniversal Health Services, Inc.
$170.33-0.77%
MPSYFMorphoSys AG
$73.27+2.10%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About OBMP

What is the current price of Theralink Technologies?

Theralink Technologies is trading at N/A per share.

What is the 52-week range for Theralink Technologies?

Over the past 52 weeks, Theralink Technologies has traded between N/A and N/A.

How much debt does Theralink Technologies have?

As of the most recent reporting period, Theralink Technologies reported total debt of $19.76M.

How much cash does Theralink Technologies have on hand?

Theralink Technologies reported $997.48K in cash and cash equivalents in its most recent financial results.

What is Theralink Technologies’s dividend yield?

Theralink Technologies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services